You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 886 Combined allogeneic NK cell and Herzuma® is effective in HER2-low breast cancer preclinical model by enhancing antibody-dependent cellular cytotoxicity

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
886 Combined allogeneic NK cell and Herzuma® is effective in HER2-low breast cancer preclinical model by enhancing antibody-dependent cellular cytotoxicity
Free

 

Online download statistics by month:

Online download statistics by month: November 2022 to November 2024

AbstractFullPdf
Nov 2022236015
Dec 20225006
Jan 20233402
Feb 20233808
Mar 20232802
Apr 20233802
May 20234807
Jun 20232204
Jul 20232406
Aug 20232401
Sep 20231604
Oct 20232001
Nov 20232202
Dec 20233006
Jan 20241802
Feb 2024601
Mar 202412010
Apr 20242806
May 20241801
Jun 20242903
Jul 20241002
Aug 20243606
Sep 20242006
Oct 20242809
Nov 20241406
Total8490118